HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is a candidate for high growth investors. Here's why.

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) was identified as a Technical Breakout Setup Pattern by our stockscreener. Such a pattern occurs when we see a pause in a strong uptrend: after a strong rise the stock is consolidating a bit and at some point the trend may be continued. Whether this actually happens can not be predicted of course, but it may be a good idea to keep and eye on NASDAQ:HALO.

What is the technical picture of NASDAQ:HALO telling us.

Every day ChartMill assigns a Technical Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple technical indicators and properties.

We assign a technical rating of 10 out of 10 to HALO. In the last year, HALO was one of the better performers in the market. There are positive signs in the very recent evolution, but the medium term picture is slightly mixed.

• Both the short term and long term trends are positive. This is a very positive sign.
• When comparing the yearly performance of all stocks, we notice that HALO is one of the better performing stocks in the market, outperforming 88% of all stocks. We also observe that the gains produced by HALO over the past year are nicely spread over this period.
• HALO is part of the Biotechnology industry. There are 572 other stocks in this industry. HALO outperforms 87% of them.
• HALO is currently trading in the upper part of its 52 week range. The S&P500 Index however is currently trading near a new high, so HALO is lagging the market slightly.
• In the last month HALO has a been trading in the 47.52 - 57.46 range, which is quite wide. It is currently trading near the high of this range.

Check the latest full technical report of HALO for a complete technical analysis.

Why is NASDAQ:HALO a setup?

Next to the Technical Rating, the Setup Rating of a stock determines to which extend the stock is consolidating. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. For NASDAQ:HALO this score is currently 7:

HALO has an excellent technical rating and also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is a resistance zone just above the current price starting at 57.54. Right above this resistance zone may be a good entry point. Another positive sign is the recent Pocket Pivot signal.

Why NASDAQ:HALO may be interesting for high growth investors.

• With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), HALOZYME THERAPEUTICS INC highlights its ability to generate increasing profitability, showcasing a 69.33% growth.
• HALOZYME THERAPEUTICS INC has demonstrated strong q2q revenue growth of 34.28%, suggesting a favorable trend in the company's financials and indicating the potential for continued expansion.
• The 3-year EPS growth of HALOZYME THERAPEUTICS INC (45.64%) highlights the company's ability to consistently improve its earnings performance and suggests a positive outlook for future profitability.
• HALOZYME THERAPEUTICS INC has demonstrated strong 1-year revenue growth of 21.36%, reflecting revenue momentum and its ability to generate consistent top-line expansion. This growth underscores the company's strong market position and its potential for future success.
• In the most recent financial report, HALOZYME THERAPEUTICS INC reported a 69.33% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
• accelerating EPS growth for HALOZYME THERAPEUTICS INC: the current Q2Q growth of 69.33% exceeds the previous year Q2Q growth of 1.35%.
• HALOZYME THERAPEUTICS INC has shown positive growth in its operating margin over the past year, indicating improved operational efficiency. This growth highlights the company's ability to effectively manage costs and maximize profitability.
• With a favorable trend in its free cash flow (FCF) over the past year, HALOZYME THERAPEUTICS INC demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• With a favorable Return on Equity (ROE) of 86.69%, HALOZYME THERAPEUTICS INC demonstrates its ability to deliver attractive returns for shareholders. This metric highlights the company's effective management of assets and its profitability.
• HALOZYME THERAPEUTICS INC has surpassed EPS estimates 3 times in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
• The Relative Strength (RS) of HALOZYME THERAPEUTICS INC has consistently been strong, with a current 88.41 rating. This indicates the stock's ability to exhibit relative price outperformance and reflects its competitive strength. HALOZYME THERAPEUTICS INC demonstrates promising potential for sustained price momentum.

More high growth momentum breakout stocks can be found in our High Growth Momentum Breakout screen.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.